Study of On-treatment Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Curative Treatment at Skne University Hospital

What this Trial Is About

Researchers are investigating metastatic colorectal cancer mCRC, focusing on how the cancer evolves during treatment and the reasons why treatment sometimes fails. The study aims to understand the genetic changes of mCRC over time and how these changes relate to treatment response and patient survival. This observational study is called On-treatment Biomarkers in Metastatic ColorectAL cancer for Life On-CALL and is sponsored by Region Skane. The study involves patients diagnosed with synchronous mCRC who are receiving treatment with curative intent at Skne University Hospital. Participants will undergo chemotherapy and surgical removal of the primary tumor and any metastases, following current clinical guidelines. Blood samples will be taken multiple times during chemotherapy to analyze biomarkers. Tissue samples from tumors and metastases will be collected to study genetic diversity and tumor evolution. Participants will provide clinical and histopathological data at the start of the study. Researchers will monitor tumor remission, progression, or recurrence over a period of 10 years, alongside quality of life changes. DNA sequencing of tumor tissues and circulating tumor DNA will be performed to assess genetic heterogeneity. Blood tests will evaluate immune cells and inflammatory markers. This long-term follow-up helps reveal how tumors change and respond to treatment over time.

On-treatment Biomarkers in Metastatic Colorectal Cancer for Life